Bray GAPJ. An Historical Review of Steps and missteps in the Discovery of Anti-obesity drugs. South Dartmouth (MA): Endotext [Internet]; 2022.

Google Scholar 

Saxon DR, Iwamoto SJ, Mettenbrink CJ, McCormick E, Arterburn D, Daley MF, et al. Antiobesity medication use in 2.2 million adults across eight large Health Care organizations: 2009–2015. Obesity. 2019;27(12):1975–81.

Article  PubMed  Google Scholar 

Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167–72.

Article  PubMed  Google Scholar 

Sherman S MM, Ungureanu, Rey JA. Naltrexone/Bupropion ER (Contrave): newly approved treatment option for Chronic Weight Management in obese adults. P T. 2016;41(3):164–72.

Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obes (Silver Spring). 2013;21(11):2163–71.

Article  CAS  Google Scholar 

Emmerich SD, Fryar CD, Stierman B, Ogden CL, Obesity. and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023 Key findings Data from the National Health and Nutrition Examination Survey [Internet]. 2021. Available from: https://www.cdc.gov/nchs/products/index.htm

Després JP, Carpentier AC, Tchernof A, Neeland IJ, Poirier P. Management of obesity in Cardiovascular Practice: JACC Focus Seminar. Journal of the American College of Cardiology. Volume 78. Elsevier Inc.; 2021. pp. 513–31.

Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.

Article  PubMed Central  Google Scholar 

Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):161.

Article  PubMed  PubMed Central  Google Scholar 

Bays HE, Kirkpatrick CF, Maki KC, Toth PP, Morgan RT, Tondt J, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18(3):e320–50.

Article  PubMed  Google Scholar 

Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9(2):129–69.

Article  PubMed  Google Scholar 

Kenneth R. Feingold. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, editors. South Dartmouth (MA): MDText.com, Inc.; 2023.

Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism. 1980;29(11):1053–60.

Article  CAS  PubMed  Google Scholar 

Simonen P, Gylling H, Howard AN, Miettinen TA. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr. 2000;72(1):82–8.

Article  CAS  PubMed  Google Scholar 

Kim HJ, Jeong S, Oh YH, Park SJ, Cho Y, Park SM. Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants. Cardiovasc Diabetol. 2023;22(1):71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teng RL, Wang H, Sun BC, Cai DP, He YM. Interaction between lipoprotein (a) levels and body mass index in first incident acute myocardial infarction. BMC Cardiovasc Disord. 2020;20(1):350.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piccirillo F, Mastroberardino S, Nusca A, Frau L, Guarino L, Napoli N et al. Novel antidiabetic agents and their effects on lipid Profile: a single shot for several Cardiovascular targets. Int J Mol Sci. 2023;24(12).

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2019;140(11):e596–646.

PubMed  PubMed Central  Google Scholar 

Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet supplemented with Extra-virgin Olive oil or nuts. N Engl J Med. 2018;378(25):e34.

Article  CAS  PubMed  Google Scholar 

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.

Article  PubMed  Google Scholar 

Mentias A, Aminian A, Youssef D, Pandey A, Menon V, Cho L, et al. Long-Term Cardiovascular outcomes after bariatric surgery in the Medicare Population. J Am Coll Cardiol. 2022;79(15):1429–37.

Article  PubMed  Google Scholar 

Chan DC, Watts GF, Ng TWK, Yamashita S, Barrett PHR. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest. 2008;38(10):743–51.

Article  CAS  PubMed  Google Scholar 

Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–38.

PubMed  Google Scholar 

Look AHEADR, Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–83.

Article  Google Scholar 

Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev. 2016;17(10):1001–11.

Article  CAS  PubMed  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

Article  PubMed  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA et al. /ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.

Andersen RE, Wadden TA, Bartlett SJ, Vogt RA, Weinstock RS. Relation of weight loss to changes in serum lipids and lipoproteins in obese women. Am J Clin Nutr. 1995;62(2):350–7.

Article  CAS  PubMed  Google Scholar 

Paluch AE, Boyer WR, Franklin BA, Laddu D, Lobelo F, Lee DC, et al. Resistance Exercise training in individuals with and without Cardiovascular Disease: 2023 Update: A Scientific Statement from the American Heart Association. Circulation. 2024;149(3):e217–31.

Article  PubMed  Google Scholar 

Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National Lipid Association Recommendations for patient-centered management of Dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 Suppl):S1–e1221.

Article  PubMed  Google Scholar 

Brown JD, Buscemi J, Milsom V, Malcolm R, O’Neil PM. Effects on cardiovascular risk factors of weight losses limited to 5–10. Transl Behav Med. 2016;6(3):339–46.

Article  PubMed  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.

Article  CAS  PubMed  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22.

Article  PubMed  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.

Article  CAS  PubMed  Google Scholar 

Deacon CF, Ahrén B. Physiology of incretins in health and disease. Rev Diabet Stud. 2011;8(3):293–306.

Article  PubMed  PubMed Central  Google Scholar 

Wegovy [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2024.

Zepbound [package insert]. Indianapolis, IN: Lilly US, LLC; 2024.

Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223–6.

Article  PubMed  PubMed Central